title: Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy.
authors.affiliation: Division of Medical Oncology, Cantonal Hospital, St. Gallen, Switzerland.
authors.forename: W
authors.initials: W
authors.lastname: Korte
authors.forename: C
authors.initials: C
authors.lastname: Jost
authors.forename: S
authors.initials: S
authors.lastname: Cogliatti
authors.forename: U
authors.initials: U
authors.lastname: Hess
authors.forename: T
authors.initials: T
authors.lastname: Cerny
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D015850:Interleukin-6; D000069283:Rituximab